Home » Newsletters » BioWorld Science

BioWorld Science

July 6, 2007

View Archived Issues

Novel neurologic compounds disclosed in recent UCB and NeuroSearch patents

Recent Otsuka and Basilea patents claim novel therapeutic agents for dermatological disorders

Novel treatment option for sepsis disclosed in recent patent

PKC-delta: a new target for the treatment of hepatic insulin resistance

MK-0364, MK-0493 studied in obese subjects

Snapshots of miscellaneous treatments for diabetes from the ADA meeting

Algeta enters new collaboration to expand TH-1 targeted cancer therapy program

Phosphodiesterases identified as potential targets in migraine

Targets in migraine: CGRP antagonists

Orexin system involved in headache pathogenesis

New clinical information on R-115866 and adalimumab in psoriasis

Tetravalent dengue vaccine protects against dengue virus infection in macaques

BioDelivery Sciences completes pre-NDA meeting with FDA

Bioalliance licenses Loramyc to Par Pharmaceutical

Positive phase I results for Acrux's combination contraceptive spray

Biogen Idec and Cardiokine to codevelop lixivaptan for hyponatremia

GTx evaluates Ostarine in phase IIb for treatment of cancer cachexia

Biomira files IND for phase I trial of HIF-1 alpha inhibitor PX-478

Recent Auspex patent discloses new treatment option for substance abuse and dependence

Pediatric study evaluates vaccine to prevent RSV and PIV-3 infections

Phase II study of A-002 completes enrollment

Promising results of novel live attenuated vaccine against salmonellosis infection

Nanocarrier-based long-acting GLP-1 mimetic improves blood glucose control in diabetic rats

Japanese approval sought for mirtazapine

Kyoto University and Astellas Pharma to coresearch immunoregulation drugs

FDA agrees on SPA for crofelemer phase III trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...